Related Experiment Video
Updated: Sep 30, 2025
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Direct Oral Anticoagulants and Coronary Artery Disease
Ravi Choxi1, Kunal Kapoor1, Nigel Mackman2
1Department of Medicine, Virginia Commonwealth University, Richmond (R.C., K.K., I.S.J.).
Insights
Direct oral anticoagulants show promise for managing coronary artery disease and preventing recurrent ischemic events. Further research is needed to balance their benefits against bleeding risks and optimize treatment regimens.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Coronary artery disease (CAD) is a major global health concern, leading to significant morbidity and mortality.
- Acute coronary syndrome is a frequent initial presentation, and patients with existing CAD face high risks of recurrent ischemic events, even with antiplatelet therapy.
Purpose of the Study:
- To review clinical data on direct oral anticoagulants (DOACs) in various CAD patient populations.
- To evaluate the balance between ischemic protection and bleeding risk with DOACs.
- To summarize DOAC use in periprocedural settings for percutaneous coronary intervention (PCI).
Main Methods:
- Systematic review of clinical trial data.
- Analysis of pharmacological mechanisms of DOACs (thrombin and factor Xa inhibition).
- Evaluation of safety and efficacy outcomes in CAD patients.
Main Results:
- DOACs offer potential benefits in preventing atherothrombotic events in CAD.
- Balancing antithrombotic efficacy with bleeding complications is crucial.
- Periprocedural DOAC use in PCI requires careful consideration of specific patient factors.
Conclusions:
- Optimal DOAC and antiplatelet combinations are needed to maximize ischemic benefit while minimizing bleeding.
- Future strategies may involve upstream coagulation cascade inhibition (e.g., FXIa, FXIIa inhibitors).
- Further studies are essential to define the precise role of DOACs in comprehensive CAD management.
Abstract:
Coronary artery disease is a leading cause of morbidity and mortality worldwide. Acute coronary syndrome as a first presentation is common and patients with established disease have a high rate of recurrent ischemic events, despite antiplatelet therapy. Over the past several years, direct oral anticoagulants have become available and have been studied in patients with coronary artery disease. These medications directly inhibit either thrombin or factor Xa which contribute to atherothrombosis. This review will summarize the clinical data regarding the use of direct oral anticoagulants in different patient populations with coronary disease and the balance between protection against ischemia and bleeding. Additionally, the review will summarize the available data on the use of direct oral anticoagulants periprocedurally in patients undergoing percutaneous coronary intervention. The future direction of coronary artery disease and the role of direct oral anticoagulants will rely on further studies determining the optimal combination of antiplatelet and oral anticoagulant regimens that derive ischemic benefit without increased rates of bleeding. Additional upstream blockade of the coagulation cascade with factor XIIa and factor XIa inhibitors may also improve treatment in the future.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:27Coronary Artery Disease V: Interprofessional Care
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:26Coronary Artery Disease IV: Preventive Measures
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:30Coronary Artery Disease I: Introduction